

INVESTOR UPDATE WEBINAR

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) (“**NeuroScientific**” or “**the Company**”) wishes to advise shareholders and investors that the Company will be conducting a live investor update on Wednesday 7th September 2022.

Managing Director and CEO, Mr Matt Liddelow will be providing an investor update to discuss the HREC decision to not approve a Phase I Clinical Trial for EmtinB™.

Following the update, there will be a Q&A session, where Matt will answer investors’ questions.

Please feel free to send questions in advance to Lucas Robinson at info@corporatestorytime.com

The company invites shareholders and investors to participate in this online event by registering via the link below:

https://us06web.zoom.us/webinar/register/WN_Fq4Tccl_Sgg3p5w0AsK7MA

Start time:

12.00pm Perth Time (AWST) / 14.00pm Sydney Time (AEST)

A link to the replay of the webinar will be made available on the NeuroScientific’s digital media accounts as soon as it is available for those unable to attend the live session.

Authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.